MANAMA: Researchers in Bahrain are studying if a nasal spray could prevent the coronavirus (Covid-19) infection.
The National Health Regulatory Authority (NHRA) yesterday announced that it has authorised a clinical study to evaluate the use of Enovid nasal spray to treat Covid-19.
Studies on the Canadian product developed by SaNOtize have shown that early treatment reduced the effects of the virus.
Researchers witnessed around 95 per cent reduction in viral replication in the first 24 hours of infection and more than 99pc within 72 hours.
NHRA said in a statement that the authorisation follows a medical study by relevant authorities at the Health Ministry.
“Enovid will be tested on volunteers diagnosed with Covid-19 who are suffering from mild symptoms,” it said.
“Once trial is completed and medical data analysed, the spray will be approved for use in preventing and treating mild Covid-19 cases.
“It may be sold in pharmacies without prescription.”
The spray has proven antimicrobial properties to treat bacterial, fungal and viral infections.
According to the manufacturers, it releases a small dose of nitric oxide designed to kill viruses in the upper airways.
This prevents them from incubating and spreading to the lungs by providing a physical and chemical barrier.
SaNOtize has claimed that the product is safe and no side effects have yet been recorded.
&uuid=(email))